Articles tagged with Colon Cancer
Researchers at Wake Forest Baptist Medical Center have identified distinct genetic patterns between cancer of the appendix and colon cancer. The study found that gene expression profiles differ significantly between the two types of cancer, suggesting a need for fresh approaches to treatment.
Virtual colonoscopies are comparably effective to standard colonoscopy in detecting colorectal cancer and precancerous polyps. The Colon Cancer Alliance and ACR urge Medicare to cover seniors for screening CT colonography, which is endorsed by the American Cancer Society.
A study published in The New England Journal of Medicine found that removing polyps by colonoscopy prevents not only colorectal cancer development but also deaths from the disease. Patients who underwent the procedure had a 53% lower death rate from colorectal cancer compared to those without removed polyps.
Researchers at MGH Cancer Center have discovered a potential treatment target for KRAS-mutant colon cancer, which may lead to new strategies for treatment-resistant tumors. Targeting TAK1 and BMP pathways may induce tumor cell death, offering hope for patients with KRAS-dependent colon cancers.
Researchers have identified an imbalance in the HNF4A gene variant as a potential biomarker for colon cancer. The study suggests that certain genetic variations may make individuals more susceptible to the disease, and drugs targeting Src kinase activity could potentially prevent or treat it.
Researchers found that rats given daily multivitamin and mineral supplements showed an 84% reduction in pre-cancerous lesions and did not develop tumors when exposed to carcinogens. The study suggests that regular supplement use could help protect against colon cancer, giving cancer patients valuable guidance.
A 1993 Chevrolet Corvette 40th Anniversary coupe was sold at the Barrett-Jackson Scottsdale Auction, raising $120,000 for cancer research at TGen. The funds support research into colon and prostate cancer in memory of Russ and Brian Jackson.
Scientists found that caffeoylquinic acid derivatives from mate tea induce apoptosis in human colon cancer cells, reducing markers of inflammation. The study suggests mate tea has potential as an anti-cancer agent and may be beneficial for other diseases associated with inflammation.
Researchers have discovered that luteolin, a flavonoid found in fruit and vegetables, can inhibit the activity of cell signaling pathways important for colon cancer cell growth. This inhibition leads to reduced IGF-II secretion, decreased receptor expression, and ultimately, cell death.
A recent study found that adding oxaliplatin to adjuvant chemotherapy for stage III colon cancer patients in the general population improved overall survival rates. The research also showed that this combination therapy was effective across various practice settings, including older and minority patients with comorbid conditions.
Researchers discovered a gene that protects against colorectal cancer by causing cell death, but this mechanism is often blocked in human cancers. The gene, DCC, codes for a 'dependence receptor' that induces apoptosis when it's depleted of ligands.
A study published in JAMA Network found that patients with myotonic muscular dystrophy are at an increased risk of developing certain types of cancer, including endometrial, brain, ovarian, and colon cancer. The study analyzed data from over 1,600 patients and found a significant excess of these cancers compared to the general population.
Research found that people with myotonic muscular dystrophy are at higher risk for developing four specific types of cancer. Additionally, there may be an increased risk for other cancers such as eye, thyroid, pancreas, and female reproductive organs. Patients should prioritize cancer screening, particularly colon cancer screening.
Almac's innovative test identifies patients who may benefit from chemotherapy, offering a breakthrough in managing stage 2 colon cancer. The technology uses genetic signatures to predict cancer recurrence, providing doctors with a valuable tool to improve patient outcomes.
Research at Johns Hopkins Medicine reveals that Bacteroides fragilis causes colon inflammation and increases activity of a gene called spermine oxidase (SMO), leading to DNA damage and tumor formation. A compound blocking SMO enzyme activity prevented DNA damage in cells.
Research suggests that adding ascorbate to hot dogs reduces N-nitroso compounds, potentially linked to colon cancer. However, colon cancer incidence rates have not changed since 1978.
Two independent research teams identify Fusobacterium in colon cancer tissue, a finding that could lead to new avenues for diagnosis and treatment of the disease. The bacteria were found more often in colon cancer tissues than normal tissue, sparking potential links between infection and colorectal tumors.
Researchers have discovered strikingly high levels of Fusobacterium in colorectal tumors, suggesting a potential role in the disease. The findings offer an enticing lead for further research into diagnosing, preventing, and treating colon cancer.
A study published in the Journal of the National Cancer Institute found that African-American patients with resected stage II and III colon cancer experienced poorer overall and recurrence-free survival compared to whites. The five-year relative survival rates for black and white colorectal cancer patients were 57% and 68%, respectively.
Researchers at Duke University have developed a technology that uses angle-resolved low coherence interferometry to detect pre-cancerous cells in the colon. The device shines short bursts of light into tissue samples and analyzes scattered light for signs of dysplasia, with an accuracy rate of 85%.
The UT Southwestern-Parkland PROSPR Center aims to optimize colon cancer screening among Dallas residents, particularly those lacking insurance or underinsured. The partnership seeks to develop a model for screening that can be used by public hospitals nationwide.
Researchers at Medical College of Wisconsin show that CXCL12 protein inhibits metastasis in colon and melanoma cancers. The protein, naturally expressed in bone marrow and other organs prone to cancer metastasis, effectively blocks tumor growth and improves survival time.
Researchers discovered that PTK6 protein, which regulates cell growth in normal tissue, activates proliferation of damaged cells in cancerous breast tissue. Mice lacking PTK6 gene were highly resistant to carcinogen-induced colon tumors.
A new study published in the Journal of the American Dietetic Association found that consuming brassica vegetables and apples may lower the risk of proximal colon cancer. In contrast, increasing fruit juice consumption was associated with an increased risk of rectal cancer.
Researchers found that soy peptide lunasin binds to receptors in highly metastatic colon cancer cells, preventing them from attaching to the liver. Combining lunasin with chemotherapy drug oxaliplatin resulted in a sixfold reduction in new tumor sites.
Case Western Reserve University School of Medicine has been awarded a $11.3 million grant from the National Cancer Institute to establish a center for research on gastrointestinal cancers. The center will focus on translational research to develop new tests, treatments, and prevention methods for colon and esophageal cancers.
Researchers at Winship Cancer Institute of Emory University have identified a way to keep the cancer-preventive properties of celecoxib while avoiding its risks. The study shows that celecoxib inhibits an enzyme called GSK3 in lung cancer cells, causing apoptosis and disappearance of a protein called c-FLIP.
Researchers have identified a protein that plays a critical role in heart development and may also be a therapeutic target for halting colon cancer metastasis. BVES expression was found to be low in all stages of colon cancer and decreased levels were observed in many other types of epithelial cancers.
A significant increase in lymph node evaluation during colon cancer operations occurred over two decades, but this was not associated with a corresponding rise in node-positive cancers. Patients with high lymph node evaluation experienced lower relative hazard of death.
University of Florida researchers have developed a compound that targets and reduces growth factors and tyrosine kinases in colon cancer cells, leading to effective tumor suppression without toxicity. The modified apratoxin S4 shows promise as a novel anticancer therapy.
Researchers at the University of Houston discovered the potential for estrogen hormone compounds to prevent colon cancer by activating estrogen receptors. They also identified a key gene involved in breast cancer tumor cell growth, opening new opportunities for targeted therapeutics.
A new process has been developed to identify patients at risk of Lynch syndrome, a genetic mutation that increases cancer risk. The process uses two inexpensive tests to eliminate possible carriers before full genome sequencing, significantly reducing costs and improving accuracy.
Researchers confirm vitamin D's role in slowing down colon cancer cell growth and proliferation. The study found that a lack of vitamin D increases the aggressiveness of colon cancer, highlighting its potential as an anti-tumor agent.
A new study developed a cost-effective way to identify patients at risk for Lynch syndrome, which could lead to earlier screenings and improved outcomes for colon and other cancers. The process uses two relatively inexpensive tests to eliminate possible carriers before full genome sequencing is required.
A recent study published in Nutrition and Cancer found that high consumption of these foods was associated with a reduced risk of colon polyps by 33-40%, confirming the results of past studies. The protective effects may be due to their cancer-fighting agents, including fiber and detoxifying compounds.
Researchers at UT Southwestern Medical Center found at least 70 genetic mutations involved in the formation of colon cancer, surpassing previous estimates. This new understanding could lead to more effective treatments targeting multiple genes and pathways simultaneously.
Researchers found that testing every new colon cancer patient for Lynch syndrome can reduce cancer deaths at a reasonable cost. Testing multiple family members after the initial diagnosis is crucial to spreading the benefit across more relatives, according to the study.
A USC team identified a genetic marker that predicts patient response to cetuximab-based therapy for locally advanced rectal cancer. The study found that 45% of patients with a specific EGF61 variant emerged disease-free after treatment.
A large cohort study found that high folate intake was associated with a reduced risk of colorectal cancer. The study also distinguished between natural and synthetic forms of folate and found no increased risk among participants consuming high levels of folate through supplements or fortification.
A Johns Hopkins team discovered that cancer cells exhibit a universal 'chaotic' pattern of methylation, leading to unpredictable gene function and increased randomness. This finding may require a new approach to cancer therapy, focusing on helping cancer cells return to normal instead of just killing them.
A new study by Brigham Young University researchers found that married individuals have a 14 percent lower risk of colon cancer death compared to unmarried patients. Married patients were also diagnosed at earlier stages of the disease and received more aggressive treatment, contributing to improved survival odds.
Scientists have discovered that niclosamide, a drug previously used to treat tapeworm infections, can silence a gene that triggers colon cancer metastasis. In mouse studies, the compound inhibited the formation of metastases in colon cancer cells.
Patients with mismatch repair defects have lower tumor recurrence rates, longer remissions, and improved overall and disease-free survival compared to those without the defects. The study suggests that these defects are associated with a reduced response to 5-FU therapy, particularly in patients with inherited defects.
A new study of U.S. veterans ages 70 and older found that healthy seniors benefit most from current colon cancer screening methods, while less healthy veterans may experience a net burden. The study highlights the need to target screening for those who are likely to benefit and re-evaluate screening for those who are not.
A new study by Henry Ford Hospital researchers found that nurse-driven, open-access colonoscopy programs are as effective and safe as traditional consultations with a gastroenterologist. The study compared outcomes of 15,901 patients in an open-access program to 6,861 patients who received outpatient consultation prior to screening.
Researchers at Tufts University have developed a device that can help reduce patient discomfort during colonoscopies by detecting and preventing 'looping' of the scope. The EFOST technology uses fiber optic bend sensors to create a visual image of the scope's position and shape, allowing doctors to make adjustments in real-time.
A survey of US primary care physicians found that making treatment recommendations changes the way physicians think about medical decisions. In scenarios involving colon cancer and avian influenza, physicians chose different treatments for themselves versus those they recommended to patients.
Researchers at Fox Chase Cancer Center found that naproxen and its derivative NO-naproxen reduce tumor formation in mutant mice. The data also suggests that naproxen blocks a key step in colon cancer formation, which could lead to the development of new chemopreventive agents.
CTC utilization has tripled in recent years, increasing access to colorectal cancer screening, and potentially saving lives through early detection of disease. The study suggests an opportunity for more people to be screened due to CTC's alternative to conventional optical colonoscopy.
Researchers found that the protein PUMA is responsible for inducing apoptosis in intestinal epithelial cells in response to inflammation, suggesting a promising target for ulcerative colitis therapies. Meanwhile, DNA methylation studies revealed targeted gene silencing and potential cancer-initiating events.
Research suggests that specific genes are silenced by DNA methylating enzyme Dnmt3b, similar to those found in human tumors. This targeted silencing may be an initiating event in cancer development.
A 40th anniversary Corvette was sold at a Barrett-Jackson auction to benefit the TGen Cancer Research Fund, named after Jackson family members who died from colon cancer. The sale raised over $250,000 for the fund, with all proceeds going towards life-changing research.
A research team at the University of Colorado Cancer Center has identified a new enzyme biomarker, ALDH1B1, present in nearly all colon cancer cells, which could help physicians diagnose colon cancer earlier and treat it more effectively.
A new clinical trial, sponsored by the National Cancer Institute, is testing whether rosuvastatin reduces the risk of recurrent colon cancer. The five-year study involves 1,740 patients and will determine if statins are effective in preventing colon cancer.
Researchers at Tel Aviv University discovered that curcumin amplifies the therapeutic activity of anti-inflammatory drugs used to treat colon cancer. This combination has already shown promising results in human clinical trials and may alleviate unwanted side effects.
Researchers at the University of Missouri have discovered biomarkers in mouse feces that can predict inflammation-associated colon cancer. This breakthrough could lead to a new method for detecting early-stage colon cancer in humans, potentially eliminating the need for colonoscopies.
A genetically tweaked probiotic has nearly eliminated colon inflammation in mice with colitis, halting disease progression by 95%. The novel probiotic strain may prove useful in colon cancer, another disease triggered by inflammation.
A new study led by researchers at WashU Medicine found that consistent exercise is associated with a lower risk of dying from colon cancer. The study analyzed data from over 150,000 men and women and found that those who exercised for at least 10 years had the lowest risk of colon cancer death.
A new study from the University of Michigan Comprehensive Cancer Center found that chemotherapy delays are common among patients with surgical complications after colorectal cancer surgery. The study, which analyzed data from 17,108 patients, suggests that surgical complications can have long-term impacts on quality of care.
A Vanderbilt University Medical Center researcher has identified a new lead for compounds that block the Wnt signaling pathway, implicated in over 90% of sporadic colon cancers. The approved anti-parasite drug pyrvinium was found to inhibit Wnt signaling and cell proliferation in cultured colon cancer cells.